SNCA and Parkinson disease: Emamzadeh and Surguchov (2018) suggested that PD can be identified with high levels of GFAP. The current study showed the elevated levels of GFAP in the striatum and substantia nigra. Thus, we suggest that this model would be excellently suited to study the non-motor dysfunctions of PD by loss of dopaminergic nigrostriatal neurons with high levels of GFAP. However, various proteins, as well as TH and α-synuclein, are involved in the mechanisms underlying pathological and behavioral phenotypes of PD (Blesa and Przedborski, 2014).